Ironwood Pharmaceuti (IRWD) Stock Price, Quote & News

Company Profile

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA name...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 621 7722

Fax: 617 494 0480

Website: ironwoodpharma.com

Address:

100 Summer Street, Suite 2300, Boston, United States

wtzou May. 1 at 10:47 PM

$IRWD $5, $6, $7—-> $11 mark this post

1 · Reply

lucullus1 May. 1 at 9:51 PM

$IRWD I offered a few of my May options for sale. The spread. Was .30 -50. I offered at .46 and someone took them. Maybe this augurs well for the near future

1 · Reply

raylin May. 1 at 8:11 PM

$IRWD Pre ER move? Need a knockout to retake $5.

0 · Reply

MalekJ May. 1 at 8:09 PM

$IRWD Very good intelligent discussions by some of the members here, nice to see for a change on Stocktwits.

0 · Reply

jskstocks May. 1 at 7:37 PM

$IRWD merger Monday?

1 · Reply

raylin May. 1 at 5:58 PM

$IRWD Cmon $8, then sale at $12-15 with a public event of McCourt and Denner in a cage match.

1 · Reply

wtzou May. 1 at 12:16 PM

$IRWD what are thoughts on which way we are voting

1 · Reply

StockTwitsGhost May. 1 at 12:01 AM

$IRWD iN mY HuMbLe oPiNiOn, when a board member’s activist fund holds 10% of your company and the board unanimously rubber-stamps a $1.2 billion no-contingency pipeline bet on an unproven drug, it stops looking like strategic vision and starts smelling like activist gambling with other people’s money. 🫳🏽🎤

1 · Reply

wtzou Apr. 30 at 11:43 PM

$IRWD can we at least all agree that management are idiots for paying $1.1B cash upgront for VectivBio in 2023? No contingency for apraglutide FDA approval. . Who does that?

3 · Reply

StockTwitsGhost Apr. 30 at 9:53 PM

$IRWD Larry 🦜 sees the daily manipulation for what it is—driven by petty inconsequential men with Oedipus complexes, pulling strings to distract from their own glaring inadequacies. Larry 🦜 words Three consecutive quarters with no live call — Q1, Q2, and Q3 2025 — during the exact period the company was in crisis mode: the apraglutide STARS-2 near-failure, covenant stress, Goldman strategic review uncertainty, and the rebate-driven revenue collapse. They went dark on investor dialogue precisely when the news was worst. The May 7 call is only the second live investor call since the crisis period. That context matters. Management is back at the podium with a recovering story — strong Linzess numbers, debt repayment on track, and potentially strategic alternatives progress to discuss. This is not a routine quarterly check-in. It’s a rehabilitation narrative with live Q&A, which makes the content of that call considerably more significant than a typical quarterly earnings event.

2 · Reply

Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

Apr 23, 2026, 7:05 AM EDT - 8 days ago

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

SBS

Mar 11, 2026, 4:00 PM EDT - 7 weeks ago

Ironwood Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 4, 2026, 4:05 PM EST - 2 months ago

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Feb 25, 2026, 8:30 AM EST - 2 months ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 7:05 AM EST - 2 months ago

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

Feb 18, 2026, 4:21 PM EST - 2 months ago

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call

Jan 2, 2026, 7:05 AM EST - 4 months ago

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

Nov 10, 2025, 7:05 AM EST - 6 months ago

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

Oct 24, 2025, 8:10 AM EDT - 6 months ago

Ironwood Stair & Rail Inc. Recognised With 2025 Consumer Choice Award for Stairs and Railings in Southern Alberta

Aug 7, 2025, 7:05 AM EDT - 9 months ago

Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

May 7, 2025, 12:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 7:05 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

Apr 25, 2025, 7:05 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

Apr 14, 2025, 2:19 PM EDT - 1 year ago

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

Apr 14, 2025, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

Feb 20, 2025, 4:00 PM EST - 1 year ago

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

Jan 29, 2025, 4:30 PM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Status Update

Jan 29, 2025, 4:05 PM EST - 1 year ago

Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

Jan 17, 2025, 8:07 AM EST - 1 year ago

Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications

Dec 4, 2024, 12:30 PM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:01 PM EST - 1 year ago

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 2:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 4:01 PM EST - 1 year ago

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024

Oct 24, 2024, 4:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

Sep 5, 2024, 2:15 PM EDT - 1 year ago

Ironwood Pharmaceuticals Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:01 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

Jul 25, 2024, 4:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call

Jun 28, 2024, 11:00 AM EDT - 2 years ago

The Schall Law Firm Starts Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Begin Conversation

Jun 26, 2024, 3:30 PM EDT - 2 years ago

The Schall Law Firm Initiates Inquiry Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Incurred Losses To Initiate Dialogue

Jun 25, 2024, 2:45 PM EDT - 2 years ago

The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Suffered Losses To Initiate Contact

Jun 24, 2024, 4:45 PM EDT - 2 years ago

The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Establish Communication

Jun 23, 2024, 11:00 AM EDT - 2 years ago

The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors With Losses To Connect

Jun 22, 2024, 11:00 AM EDT - 2 years ago

The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Reach Out

Jun 19, 2024, 4:20 PM EDT - 2 years ago

Allegations Against Ironwood Pharmaceuticals Inc The Schall Law Firm Initiates Probe And Urges Investors With Losses To Make Contact

Jun 18, 2024, 4:00 PM EDT - 2 years ago

Claims Against Ironwood Pharmaceuticals Inc The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Reach Out

Jun 18, 2024, 9:00 AM EDT - 2 years ago

Ironwood Pharmaceuticals Transcript: AGM 2024

Jun 11, 2024, 7:00 PM EDT - 2 years ago

Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Reach Out

Jun 9, 2024, 11:00 AM EDT - 2 years ago

Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Urges Investors With Losses To Contact Them

Jun 8, 2024, 11:00 AM EDT - 2 years ago

Allegations Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Initiates Probe And Invites Investors With Losses To Get In Touch

Jun 7, 2024, 3:00 PM EDT - 2 years ago

Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Contact Them

Jun 6, 2024, 1:00 PM EDT - 2 years ago

Accusations Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Initiates Investigation And Invites Investors With Losses To Reach Out

Jun 6, 2024, 9:00 AM EDT - 2 years ago

Ironwood Pharmaceuticals Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 1:30 PM EDT - 2 years ago

Ironwood Pharmaceuticals, Inc. Accusations: Schall Law Firm Announces Investigation and Calls for Investors with Losses to Connect

Jun 4, 2024, 3:00 PM EDT - 2 years ago

The Schall Law Firm Declares an Inquiry into Accusations Against Ironwood Pharmaceuticals, Inc. and Advocates for Investors with Losses to Reach Out

Jun 2, 2024, 11:00 AM EDT - 2 years ago

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

May 31, 2024, 6:15 PM EDT - 2 years ago

ONGOING INVESTIGATION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

May 30, 2024, 4:01 PM EDT - 2 years ago

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 21, 2024, 6:00 AM EDT - 2 years ago

Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

May 13, 2024, 10:00 AM EDT - 2 years ago

Ironwood Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference

May 9, 2024, 8:30 AM EDT - 2 years ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q1 2024

Feb 29, 2024, 8:00 AM EST - 2 years ago

Ironwood Pharmaceuticals Transcript: Study Result

Feb 15, 2024, 8:30 AM EST - 2 years ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2023

Jan 10, 2024, 2:15 PM EST - 2 years ago

Ironwood Pharmaceuticals Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Nov 29, 2023, 9:00 AM EST - 2 years ago

Ironwood Pharmaceuticals Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 9, 2023, 8:30 AM EST - 2 years ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q3 2023

Aug 8, 2023, 8:30 AM EDT - 2 years ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q2 2023

May 22, 2023, 8:30 AM EDT - 3 years ago

Ironwood Pharmaceuticals Transcript: M&A Announcement

May 4, 2023, 8:30 AM EDT - 3 years ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q1 2023

Mar 14, 2023, 8:00 AM EDT - 3 years ago

Ironwood Pharmaceuticals Transcript: Barclays Global Healthcare Conference

Feb 16, 2023, 8:30 AM EST - 3 years ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2022

Jan 11, 2023, 12:00 PM EST - 3 years ago

Ironwood Pharmaceuticals Transcript: JPMorgan Healthcare Conference

Nov 3, 2022, 8:30 AM EDT - 3 years ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q3 2022

Aug 3, 2022, 9:00 PM EDT - 4 years ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q2 2022

May 5, 2022, 8:39 AM EDT - 4 years ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q1 2022

Feb 16, 2022, 8:14 PM EST - 4 years ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2021

wtzou May. 1 at 10:47 PM

$IRWD $5, $6, $7—-> $11 mark this post

1 · Reply

lucullus1 May. 1 at 9:51 PM

$IRWD I offered a few of my May options for sale. The spread. Was .30 -50. I offered at .46 and someone took them. Maybe this augurs well for the near future

1 · Reply

raylin May. 1 at 8:11 PM

$IRWD Pre ER move? Need a knockout to retake $5.

0 · Reply

MalekJ May. 1 at 8:09 PM

$IRWD Very good intelligent discussions by some of the members here, nice to see for a change on Stocktwits.

0 · Reply

jskstocks May. 1 at 7:37 PM

$IRWD merger Monday?

1 · Reply

raylin May. 1 at 5:58 PM

$IRWD Cmon $8, then sale at $12-15 with a public event of McCourt and Denner in a cage match.

1 · Reply

wtzou May. 1 at 12:16 PM

$IRWD what are thoughts on which way we are voting

1 · Reply

StockTwitsGhost May. 1 at 12:01 AM

1 · Reply

wtzou Apr. 30 at 11:43 PM

$IRWD can we at least all agree that management are idiots for paying $1.1B cash upgront for VectivBio in 2023? No contingency for apraglutide FDA approval. . Who does that?

3 · Reply

StockTwitsGhost Apr. 30 at 9:53 PM

2 · Reply

Bio_Invest101 Apr. 30 at 8:08 PM

$IRWD ER 8:30 AM May 7 https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2026-Investor-Update-Call/default.aspx

0 · Reply

WiseSolution Apr. 30 at 3:37 AM

$IRWD irwd revenue has been averaging around 36% of the sales of Abbv which would place revenue around 101m. The wild card is all the cost cutting going on which will help increase eps and cash as compared to past percentages.

1 · Reply

raylin Apr. 29 at 11:14 PM

$IRWD We are the Rodney Dangerfield of stocks. No Respect. Sales increase huge, intend to eliminate the debt, we go down. Tommy needs an A Game at ER.

0 · Reply

StockTwitsGhost Apr. 29 at 9:03 PM

$IRWD Short Sellers Manifesto 🤺 He wears platform shoes so he can look investors in the eye while still shorting everything that stands taller than his ego. The only position he never exits is self denial, and even that’s trading below par. He is the most interesting man in the world.

0 · Reply

Bio_Invest101 Apr. 29 at 7:33 PM

$IRWD Another Buyout deal at sweet $1.9 Bn 10th in April alone https://www.fiercepharma.com/pharma/chiesi-lays-out-19b-bolster-rare-disease-offerings-kalvista-and-its-hae-med-ekterly

0 · Reply

wtzou Apr. 29 at 7:05 PM

$IRWD The next earnings report (Q1 2026) is expected on May 11, 2026, with analysts projecting an EPS of $0.21

0 · Reply

Solaf Apr. 29 at 6:56 PM

$IRWD fraud market btw

0 · Reply

Delfonzo Apr. 29 at 6:43 PM

$IRWD Linzess (linaclotide) generated $283 million in sales during the first quarter of 2026, according to reported Q1 earnings Key 2026 Sales & Guidance Details Q1 Performance: The $283 million in sales represents a 90.9% increase, driven by strong demand and a, lower list price implemented on January 1, 2026, to improve net pricing. Full-Year 2026 Guidance: Ironwood Pharmaceuticals projects U.S. Linzess net sales to reach $1.125 – $1.175 billion for the full year 2026.

0 · Reply

StockTwitsGhost Apr. 29 at 6:37 PM

$IRWD OliveDrabGreen 002 🤺

0 · Reply

lucullus1 Apr. 29 at 4:45 PM

$IRWD well ABBV has told us Lizness sales. So the market has the information needed to make a decision and you can’t help but feel that the share price is going to be controlled until ABBV take the company out at a low price

1 · Reply

galaxySky Apr. 29 at 2:51 PM

$IRWD seems like a beat and the insurance repricing appears to have worked. in with a little bit for the earnings upcoming. abbvie results don’t look properly priced in yet.

0 · Reply

revuelto Apr. 29 at 2:46 PM

$IRWD Mr. Michael, I am positive $ABBV is interested in acquiring Ironwood and its assets. Where do things currently stand on the paperwork and can the process be expedited?.

0 · Reply

Market Cap	672.61M
Revenue (ttm)	296.15M
Net Income (ttm)	24.02M
EPS (ttm)	N/A
PE Ratio	18.04
Forward PE	4.72
Profit Margin	8.11%
Debt to Equity Ratio	-2.23

Volume	1,737,500
Avg Vol	2,816,046
Day's Range	N/A - N/A
Shares Out	163.06M
Stochastic %K	94%
Beta	0.17
Analysts	Sell
Price Target	$6.10